Participating Faculty

Published on: 
Supplements and Featured Publications, Major Depressive Disorder and Functional Impairment: Key Concepts for Enhancing Patient Outcomes, Volume 15, Issue 11

Major Depressive Disorder and Functional Impairment: Key Concepts for Enhancing Patient Outcomes

This supplement to The American Journal of Managed Care reviews the unique nature of the functional impairment that is associated with major depressive disorder, with special focus on the importance of achieving early, quality disease remission and the need for long-term maintenance therapy.

Participating Faculty

Kathleen M. Dorries, PhD

Senior Medical Writer


Wayne, New Jersey


Jean Endicott, PhD

Professor of Clinical Psychology

Department of Psychiatry

Columbia University

New York, New York

Wayne Katon, MD

Professor, Vice Chair, Director of Division of Health Services and Psychiatric Epidemiology

University of Washington

Medical School

Seattle, Washington

Michael S. Klinkman, MD, MS

Associate Professor

Departments of Family Medicine and Psychiatry

University of Michigan Health System

Ann Arbor, Michigan

George I. Papakostas, MD

Director, Treatment-Resistant Depression Studies

Massachusetts General Hospital

Associate Professor of Psychiatry

Harvard Medical School

Boston, Massachusetts

Faculty Disclosures

These participants report relationships with the following organizations:

Kathleen M. Dorries, PhD Employee of Advogent, which received funding for the supplement from Pfizer Inc, formerly Wyeth Research

Jean Endicott, PhD

Consultant/Advisory Board Member: Cyberonics, Lilly, Wyeth Research; Honoraria: Lilly, Wyeth Research

Wayne Katon, MD

Advisory Board Member: Lilly; Honoraria: Forest, Lilly, Pfizer, Wyeth

Michael S. Klinkman, MD, MS Scientific Advisory Board/Honoraria: Wyeth Pharmaceuticals; Medical Advisory Board: Cielo MedSolutions, LLC

George I. Papakostas, MD Consultant/Board Member: AstraZeneca, Lilly, Otsuka, Pamlab, Wyeth; Honoraria: AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Lundbeck, Otsuka, Pfizer, Wyeth; Lecturer: AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Otsuka, Pfizer


This supplement has been supported by funding from Pfizer Inc, formerly Wyeth Research.

This supplement was derived from a roundtable discussion, "Functional Outcomes: Key Endpoints in the Management of Major Depressive Disorder," which took place on April 29, 2009, and was sponsored by an unrestricted educational grant from Pfizer Inc, formerly Wyeth Research, Collegeville, Pennsylvania, awarded to the Advogent Group, Inc.

The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing inf

ormation for these products.